743 related articles for article (PubMed ID: 26824988)
1. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
3. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
4. Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
Zardavas D; Cameron D; Krop I; Piccart M
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714441
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK
Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027
[TBL] [Abstract][Full Text] [Related]
8. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Mahtani R; Holmes FA; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Vogel C;
Clin Breast Cancer; 2020 Jun; 20(3):e251-e260. PubMed ID: 32139271
[TBL] [Abstract][Full Text] [Related]
9. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Santa-Maria CA; Nye L; Mutonga MB; Jain S; Gradishar WJ
Oncology (Williston Park); 2016 Feb; 30(2):148-55. PubMed ID: 26892151
[TBL] [Abstract][Full Text] [Related]
10. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Dey N; De P; Leyland-Jones B
Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
[TBL] [Abstract][Full Text] [Related]
11. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.
Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A
Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705
[TBL] [Abstract][Full Text] [Related]
12. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
13. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer.
Yang X; Wu D; Yuan S
Technol Cancer Res Treat; 2020; 19():1533033820962140. PubMed ID: 33034269
[TBL] [Abstract][Full Text] [Related]
15. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
16. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Loibl S; de la Pena L; Nekljudova V; Zardavas D; Michiels S; Denkert C; Rezai M; Bermejo B; Untch M; Lee SC; Turri S; Urban P; Kümmel S; Steger G; Gombos A; Lux M; Piccart MJ; Von Minckwitz G; Baselga J; Loi S
Eur J Cancer; 2017 Nov; 85():133-145. PubMed ID: 28923573
[TBL] [Abstract][Full Text] [Related]
18. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
19. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
